More Medicare plans cover Humira biosimilars, but do little to encourage patient use

More Medicare plans cover Humira biosimilars, but do little to encourage patient use

A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were launched in the U.S. in 2023.

Study Supports Adalimumab Biosimilar Interchangeability for Patients with Psoriasis

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

The People vs. AbbVie | Medicines Law & Policy

Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court case against AbbVie, over AbbVie’s excessive profits on the sales of its rheumatoid arthritis medicine Humira (adalimumab).  PAF is alleging that  the company acted unlawfully in extracting excessive profits from the sales of Humira in the Netherlands, and in doing so causing displacement of care in …

Author: Ma Junhao Sun Miao Humira is a benchmark product in the global pharmaceutical industry. Its main ingredient is adalimumab, which can inhibit tumor necrosis factor-α (TNF-α) and thus reduce inflammation caused by autoimmune diseases. It covers a wide range of indications, including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis, and occupies an important position in the treatment of autoimmune diseases. Humira has…